Global Sickle Cell Anemia Drug Market Price Dosage And Clinical Pipeline Outlook 2024

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-sickle-cell-anemia-drug-market-price-dosage-and-clinical-pipeline-outlook-2024.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Sickle Cell Anemia - An Inherited Blood Disorder
1.1 Introduction
1.1.1 Signs and Symptoms of Sickle Cell Anemia
1.1.2 Types of Sickle Cell Disease
1.2 Antiquity of Sickle Cell Disease

2. Genetics and Diagnostics of Sickle Cell Disease
2.1 Genetic Mutations
2.2 Diagnostic Approaches for Sickle Cell Disease
2.2.1 Blood Test
2.2.2 Prenatal Testing
2.2.3 Newborn Screening
2.3 Cost Analysis of Sickle Cell Disease Diagnosis

3. Management Strategies for Sickle Cell Disease Treatment - Cost Analysis
3.1 Medication Methods
3.2 Transfusion
3.3 Bone Marrow Transplant

4. Total Annual Cost for Patients with Sickle Cell Disease
4.1 Fees for Hospitalization, Emergency Department and Professional Fees
4.2 Annual Fees for the care of an Adult Patient with Sickle Cell Disease

5. Advance Research for Treatment of Sickle Cell Anemia Disease
5.1 Introduction
5.2 Umbilical Cord Blood Transplant
5.3 Gene Therapy

6. Sickle Cell Anemia - Drug and Treatment Cost Analysis
6.1 Glutamine (Endari)
6.2 Hydroxycarbamide (Droxia, Hydrea)
6.3 Nicosan (Niprisan or Nix-0699)
6.4 Ibuprofen

7. Market Analysis of Sickle Cell Disease
7.1 Introduction
7.2 Sickle Cell Disease Market Size

8. Global Sickle Cell Anemia Drug Market Dynamics
8.1 Favorable Parameters
8.2 Challenges

9. Future Aspects of Global Sickle Cell Disease Treatment Market

10. Global Sickle Cell Anemia Drug Clinical Pipeline by Company and Phase
10.1 Sickle Cell Anemia Drug Clinical Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Phase-I
10.5 Phase-I/II
10.6 Phase-II
10.7 Phase-III

11. Marketed Sickle Cell Anemia Drug Clinical Insight
11.1 Glutamine (Endari and NutreStore)
11.2 Hydroxycarbamide (Siklos)
11.3 Hydroxycarbamide (Droxia, Hydrea, Litalir and OncoCarbide)
11.4 Nix 0699 (Hemoxin, Nicosan and Niprisan)

12. Competitive Landscape
12.1 BioMarin
12.2 Bluebird Bio Bluebird Bio
12.3 DeuteRx
12.4 Emmaus Medical
12.5 Gamida Cell
12.6 Global Blood Therapeutics
12.7 GlycoMimetics
12.8 Modus Therapeutics
12.9 Pfizer
12.10 Sancilio Pharmaceuticals
12.11 Sangamo Biosciences

Figure 1-1: Inheritance Pattern of Sickle Cell Anemia from One Generation to Next Generation
Figure 1-2: Historical Development of Sickle Cell Disease and its Therapeutic Approaches
Figure 2-1: Genetic Mutations which Occur at the Transcription and Translational Level
Figure 2-2: Pathophysiology of Sickle Cell Disease
Figure 2-3: Various Diagnostic Methods for Sickle Cell Disease
Figure 2-4: Price Analysis - Sickle Cell Diagnosis Cost with Insurance (US$), 2018
Figure 2-5: Price Analysis - Sickle Cell Diagnosis Cost without Insurance (US$), 2018
Figure 2-6: Price Analysis - CVS and Amniocentesis for Sickle Cell Anemia(US$), 2018
Figure 2-7: Global - Average NIPT Screening Cost by Technique (US$), 2018
Figure 3-1: Several Management Approaches for Sickle Cell Disease
Figure 3-2: Sickle Cell Disease - Treatment Cost Analysis by Medication (US$/Month), 2018
Figure 3-3: Acceptable Outcomes for Sickle Cell Disease Bone Marrow Transplant
Figure 3-4: Allogeneic and Autogenic Bone Marrow Transplant Cost (US$), 2018
Figure 4-1: Consultation Fees for Sickle Cell Disease (US$/Patient), 2018
Figure 4-2: Hospitalization Charges for Sickle Cell Disease (US$/Day), 2018
Figure 4-3: Price Analysis - Emergency Department Cost (US$/Patient), 2018
Figure 4-4: Emergency Department Professional Fees Billed by Severity (US$), 2018
Figure 4-5: Price Analysis - Average Hospital Charges (US$/SCD patient), 2018
Figure 4-6: Annual Cost Analysis for Tests Involved in Sickle Cell (US$/Patient), 2018
Figure 4-7: Expenditure on SCD Patient by Age (US$/Annum), 2018
Figure 5-1: Ongoing Research for the Development of Sickle Cell Disease Treatment
Figure 5-2: Umbilical Cord Blood Transplant Method for Sickle Cell Anemia
Figure 5-3: Cost Analysis - Umbilical Cord Blood Transplant (US$/Patient), 2018
Figure 5-4: Gene Therapy Method for Sickle Cell Disease Treatment
Figure 5-5: Gene Therapy - Estimated Cost of Therapy and Medication (US$/Patient),2018
Figure 6-1: Endari - Dosage by Body Weight (gram/Dose)
Figure 6-2: Endari - Dosage per day by Body Weight (gram/Day)
Figure 6-3: Endari - Packet Consumption (Number) per Dose by Weight
Figure 6-4: Endari - Packets Consumed (Number of Packets/Day)
Figure 6-5: Endari - Price Analysis for 5mg Tablet (US$/Packet), 2018
Figure 6-6: Droxia - Available Concentrations by type (mg/Tablet)
Figure 6-7: Droxia - Dosage Analysis by Weight (mg/kg)
Figure 6-8: Droxia - Price Analysis per 60 Tablet Packet (US$), 2018
Figure 6-9: Nicosan - Recommended Dosage in children and Adult (mg/Day)
Figure 6-10: Patent Approval Year in UK and US
Figure 6-11: Ibuprofen - Availability by concentration (mg and mg/ml)
Figure 6-12: Ibuprofen - Price of 6ml Intravenous Solution Vial (US$), 2018
Figure 6-13: Ibuprofen - Oral Capsule Price Analysis (US$), 2018
Figure 6-14: Ibuprofen - Price Analysis of Oral Suspension (US$), 2018
Figure 6-15: Ibuprofen - Price Analysis of Oral Tablets (US$/Packet), 2018
Figure 7-1: Burden of Rare Diseases in US and Globally (%)
Figure 7-2: Global - Incidence of Sickle Cell Disease (%), 2018
Figure 7-3: Global - Sickle Cell Anemia Childhood Survival Rates by Region (%), 2018
Figure 7-4: Global - Orphan Drugs Market Forecast (US$ Billion), 2016 - 2024
Figure 7-5: Global - Sickle Cell Disease Market Size (%), 2018
Figure 7-6: Global - Blood Disorders Market Size by Type (%), 2018
Figure 8-1: Favorable Growth Factors for the Sickle Cell Disease Treatment
Figure 8-2: Challenges to the Growth of Sickle Cell Disease Treatment
Figure 9-1: Global - Sickle Cell Disease Market Opportunity (US$ Million), 2018 -2024
Figure 10-1: Global - Sickle Cell Anemia Drug Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global - Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global - Discontinued Sickle Cell Anemia Drug Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global - Discontinued Sickle Cell Anemia Drug Pipeline by Phase (Number), 2018 till 2024






Table 3-1: Clinical Trials Addressing Transfusion Indications for Sickle Cell Disease
Table 5-2: Droxia - Dosage Analysis by Weight (mg/kg)

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.